Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.
Clofazimine: an old drug for never-ending diseases / N. Riccardi, A. Giacomelli, D. Canetti, A. Comelli, E. Intini, G. Gaiera, M.M. Diaw, Z. Udwadia, G. Besozzi, L. Codecasa, A.D. Biagio. - In: FUTURE MICROBIOLOGY. - ISSN 1746-0913. - (2020). [Epub ahead of print] [10.2217/fmb-2019-0231]
Clofazimine: an old drug for never-ending diseases
A. GiacomelliSecondo
;
2020
Abstract
Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.File | Dimensione | Formato | |
---|---|---|---|
fmb-2019-0231 clofazimine.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.46 MB
Formato
Adobe PDF
|
1.46 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.